Usher Syndrome clinical trials at UCSF
3 in progress, 0 open to eligible people
Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
San Francisco, California and other locations
Rate of Progression in USH2A-related Retinal Degeneration
Sorry, in progress, not accepting new patients
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).
San Francisco, California and other locations
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Sorry, in progress, not accepting new patients
The overall goal of this project, co-funded by the Foundation Fighting Blindness and the USHER 1F Collaborative is to characterize the natural history of disease progression in patients with PCDH15 mutations in order to accelerate the development of outcome measures for clinical trials.
San Francisco, California and other locations
Our lead scientists for Usher Syndrome research studies include Jacque Duncan, MD.
Last updated: